Human cytomegalovirus (CMV, human herpesvirus 5) is a pervasive viral pathogen and major cause of disease in infants and immunocompromised patients worldwide. One of the leading targets for vaccine development is CMV glycoprotein B (gB), which is a viral envelope protein that mediates fusion with host-cell membranes and is required for viral entry into all known cell types.